Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion (original) (raw)
Adorini L, Pruzanski M, Shapiro D (2012) Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 17–18:988–97 Article Google Scholar
Allain CC, Poon LS, Chan CS, Richmond W et al (1974) Enzymatic determination of total serum cholesterol. Clin Chem 4:470–5 Google Scholar
Anderson ME (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 548–55
Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol
Arrese M (2010) Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol 12:660–1 Article Google Scholar
Baginski ES, Foa PP, Zak B (1967) Microdetermination of inorganic phosphate, phospholipids, and total phosphate in biologic materials. Clin Chem 4:326–32 Google Scholar
Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L et al (2014) Glucose-induced glucagon-like peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS ONE 1:e87488 Article Google Scholar
Carr TP, Andresen CJ, Rudel LL (1993) Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 1:39–42 Article Google Scholar
Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 4:771–84 Article Google Scholar
Chalasani N, Younossi Z, Lavine JE, Diehl AM et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 7:1592–609 Article Google Scholar
DeLeve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 3:287–305 Article Google Scholar
Diehl AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 3:619–38 Article Google Scholar
Furukawa S, Fujita T, Shimabukuro M, Iwaki M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 12:1752–61 Article Google Scholar
Goodwin B, Jones SA, Price RR, Watson MA et al (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 3:517–26 Article Google Scholar
Gupta NA, Mells J, Dunham RM, Grakoui A et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 5:1584–92 Article Google Scholar
Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 4:1409–39 Article Google Scholar
Ibanez P, Solis N, Pizarro M, Aguayo G et al (2007) Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 6:846–51 Article Google Scholar
Ikemoto S, Takahashi M, Tsunoda N, Maruyama K et al (1997) Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol 1(Pt 1):E37–45 Google Scholar
Ishizaki K, Iwaki T, Kinoshita S, Koyama M et al (2008) Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 1:57–64 Article Google Scholar
Kars M, Yang L, Gregor MF, Mohammed BS et al (2010) Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 8:1899–905 Article Google Scholar
Lefebvre P, Cariou B, Lien F, Kuipers F et al (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 1:147–91 Article Google Scholar
Liechti F, Dufour JF (2012) Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol S46-52
Matsubara T, Li F, Gonzalez FJ (2013) FXR signaling in the enterohepatic system. Mol Cell Endocrinol 1–2:17–29 Article Google Scholar
McConnachie LA, Mohar I, Hudson FN, Ware CB et al (2007) Glutamate cysteine ligase modifier subunit deficiency and gender as determinants of acetaminophen-induced hepatotoxicity in mice. Toxicol Sci 2:628–36 Article Google Scholar
Nie B, Park HM, Kazantzis M, Lin M et al (2012) Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology 4:1300–10 Article Google Scholar
Olaywi M, Bhatia T, Anand S, Singhal S (2013) Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 6:584–8 Article Google Scholar
Ozcan U, Yilmaz E, Ozcan L, Furuhashi M et al (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 5790:1137–40 Article Google Scholar
Pols TW, Noriega LG, Nomura M, Auwerx J et al (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 6:1263–72 Article Google Scholar
Pols TW, Noriega LG, Nomura M, Auwerx J et al (2011) The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 1:37–44 Article Google Scholar
Rafferty EP, Wylie AR, Hand KH, Elliott CE et al (2011) Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(−/−) mice. Biol Chem 6:539–46 Google Scholar
Ratziu V (2012) Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol S41-5
Stepanova M, Rafiq N, Makhlouf H, Agrawal R et al (2013) Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 10:3017–23 Article Google Scholar
Talalay P (1960) Enzymic analysis of steroid hormones. Methods Biochem Anal 119–43
Thomas C, Pellicciari R, Pruzanski M, Auwerx J et al (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 8:678–93 Article Google Scholar
Trauner M, Arrese M, Wagner M (2010) Fatty liver and lipotoxicity. Biochim Biophys Acta 3:299–310 Article Google Scholar
Trauner M, Claudel T, Fickert P, Moustafa T et al (2010) Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 1:220–4 Article Google Scholar
Tsuchida T, Shiraishi M, Ohta T, Sakai K et al (2012) Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metab Clin Exp 7:944–53 Article Google Scholar
Turley SD, Dietschy JM (1978) Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 7:924–8 Google Scholar
Watanabe M, Houten SM, Wang L, Moschetta A et al (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 10:1408–18 Article Google Scholar
Xiang Z, Chen YP, Ma KF, Ye YF, et al. (2013) The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 140
Yang JS, Kim JT, Jeon J, Park HS et al (2010) Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS ONE 11:e13858 Article Google Scholar
Zhang Y, Klaassen CD (2010) Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 11:3230–42 Article Google Scholar
Zollner G, Wagner M, Moustafa T, Fickert P et al (2006) Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 5:G923–32 Google Scholar